Welcome to our dedicated page for Scpharmaceutical news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on Scpharmaceutical stock.
scPharmaceuticals Inc. (SCPH) delivers innovative subcutaneous therapies that transform intravenous treatment protocols for heart failure and related conditions. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access timely announcements about FUROSCIX advancements, partnership agreements, and research breakthroughs. Our curated collection includes earnings reports, FDA submissions, and analyses of the company’s unique drug-device integration strategy in cardiorenal care.
Discover how SCPH’s subcutaneous delivery platform addresses healthcare cost reduction through outpatient treatment solutions. Stay informed about trial results, manufacturing updates, and market expansion efforts shaping this clinical-stage biopharma’s trajectory.
Bookmark this page for consolidated access to verified SCPH developments, carefully sourced to support informed decision-making in dynamic pharmaceutical markets.
scPharmaceuticals Inc. (SCPH) has launched FUROSCIX®, the first self-administered subcutaneous loop diuretic for chronic heart failure treatment, effective February 20, 2023. The company ended Q4 2022 with $118.4 million in cash and reported a net loss of $9.2 million for the quarter. This represents an increase from $7.3 million in Q4 2021. The company also completed a $50 million stock offering and a $100 million secured debt financing to support FUROSCIX commercialization. Expectations indicate rising operational costs in 2023 for marketing efforts. CEO John Tucker expressed optimism regarding FUROSCIX's potential impact on patient care.
FAQ
What is the current stock price of Scpharmaceutical (SCPH)?
What is the market cap of Scpharmaceutical (SCPH)?
